Sarah Cannon Research Institute acquires Clinical Development Group
CDG provides expanded capabilities in global clinical and regulatory planning, trial project management and academic relationships.
CDG president, Ann Cahill, has joined SCRI’s executive team as vice president, program development, and will report to chief medical officer Howard A. Burris III, M.D. Previously, Cahill held several leadership positions in drug development with biopharmaceutical companies including Schering-Plough and Vion Pharmaceuticals.
SCRI has opened an office in Cambridge, Mass., to serve its pharmaceutical and biotechnology partners.